Oncomed Pharmaceuticals Inc (NASDAQ:OMED): Joseph Edelman’s Perceptive Advisors filed an amended 13D.
You can check out Perceptive Advisors’ latest holdings and filings here.
Please follow Perceptive Advisors (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Perceptive Advisors or update its stock holdings.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Perceptive Life Sciences Master Fund, Ltd||0||2,470,897||0||2,470,897||2,470,897||6.5%|
Page 1 of 8 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. )*
(Name of Issuer)
common stock, par value $0.001 per share
(Title of Class of Securities)
68234X 10 2
November 6, 2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
|*||The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information |
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).